Document Detail

The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells.
MedLine Citation:
PMID:  17612559     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: An estimated 162,460 people will die of lung cancer in the United States in 2006, making it the leading cause of cancer deaths. Small cell lung cancer (SCLC) accounts for 20% of all lung cancers and exhibits aggressive behavior with early metastases. Current treatments yield five-year survival rates of 5 to 10%, indicating a need for novel therapeutic approaches. Histone deacetylase inhibitors (HDACIs) represent a new class of anticancer agents. Trichostatin A (TSA), an HDACI, has been shown to inhibit growth in several cancers. We hypothesized that TSA may inhibit proliferation of SCLC cells. MATERIALS AND METHODS: Human SCLC DMS53 cells were treated with TSA (0 to 400 nM). Light microscopy was used to assess changes in cell morphology. Western analysis was performed for acetylated histone 4 to confirm HDAC inhibition. The effect of TSA treatment on cellular growth was measured by the MTT assay. Finally, levels of BCL-2, cleaved poly(ADP-ribose) polymerase, p21, and p27 proteins were measured to look for induction of cell cycle arrest and/or apoptosis. RESULTS: DMS53 cells treated with TSA underwent dramatic changes in cell appearance. Treated cells assumed round and spindle shapes with distinct cellular borders. Western analysis demonstrated increased levels of acetylated histone 4. TSA treatment resulted in a dose-dependent inhibition of growth. Lastly, elevated p21, p27, and cleaved poly(ADP-ribose) polymerase along with decreased BCL-2 protein levels were observed. CONCLUSIONS: TSA causes morphological differentiation and dose-dependent inhibition of cell growth via cell cycle arrest and subsequent apoptosis. This suggests that TSA and other HDACIs may represent a new potential therapy for patients with SCLC.
Christopher S Platta; David Yü Greenblatt; Muthusamy Kunnimalaiyaan; Herbert Chen
Related Documents :
20219459 - Involvement of zfpip/zfp462 in chromatin integrity and survival of p19 pluripotent cells.
19210579 - Differential regulation of connective tissue growth factor in renal cells by histone de...
15194229 - Hydrolysis of nuclear phospholipids in relation with proliferative state in uterine str...
15592649 - A putative nes mediates cytoplasmic localization of apoptin in normal cells.
19013199 - Disturbed nuclear orientation and cellular migration in a-type lamin deficient cells.
18077559 - Biphasic incorporation of centromeric histone cenp-a in fission yeast.
22373529 - Transient overexpression of cyclin d2/cdk4/glp1 genes induces proliferation and differe...
16782189 - Placental alkaline phosphatase (plap) staining and human chorionic gonadotropin (hcg) p...
8631979 - Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2007-07-05
Journal Detail:
Title:  The Journal of surgical research     Volume:  142     ISSN:  0022-4804     ISO Abbreviation:  J. Surg. Res.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-09-24     Completed Date:  2007-11-07     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0376340     Medline TA:  J Surg Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  219-26     Citation Subset:  IM    
Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Carcinoma, Small Cell / drug therapy*,  pathology
Cell Cycle / drug effects
Cell Division / drug effects
Cell Line, Tumor
Enzyme Inhibitors / pharmacology*
Histone Deacetylase Inhibitors*
Hydroxamic Acids / pharmacology*
Lung Neoplasms / drug therapy*,  pathology
Grant Support
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 58880-19-6/trichostatin A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The box H/ACA RNP assembly factor Naf1p contains a domain homologous to Gar1p mediating its interact...
Next Document:  Mesenteric lymph node Tgammadelta cells induced by gastrectomy in mice suppress cell-mediated immune...